World news – SVB Leerink increases Bluebird Bio (NASDAQ: BLUE) target price to USD 72.00

0

Register at MarketBeat All Access to get access to the complete research tools of MarketBeat:

The target price of bluebird bio (NASDAQ: BLUE) was determined by analysts of SVB Leerink in a research published on Monday Benzinga reports that the note has been raised from USD 69.00 to USD 72.00. The broker currently has an « Outperform » rating for the biotech company’s stock. SVB Leerink’s price target indicates a potential plus of 140.16% compared to the share’s last closing price.

A number of other research analysts recently also rated the company. BMO Capital Markets raised its price target for Bluebird Bio from USD 31.00 to USD 35.00 and rated the company in a report on Monday as « market performance ». Zacks Investment Research upgraded Bluebird Bio from a « sell » rating to a « hold » rating in a report on Thursday, February 18, and set a price target of $ 29.00 on the stock. Maxim Group downgraded Bluebird Bio from a « Buy » rating to a « Hold » rating in a report on Wednesday December 9th. Morgan Stanley cut its price target on Bluebird Bio from $ 50.00 to $ 45.00 and posted an « equilibrium » rating for the stock in a report on Monday March 8th. Finally, Bank of America downgraded Bluebird Bio from a « buy » rating to a « neutral » rating in a report on Tuesday, February 16. Thirteen analysts have rated the stock with a hold rating and five with a buy rating. The stock has an average rating of « Hold » and a consensus price target of $ 59.38.

Bluebird Bio stock opened at $ 29.98 on Monday. The company has a market cap of $ 2.01 billion, value for money of -2.73, and a beta of 1.89. bluebird bio has a 1 year low of $ 24.24 and a 1 year high of $ 72.50. The company’s 50-day moving average price is $ 33.74 and the two-day moving average is $ 45.50. (adsbygoogle = window.adsbygoogle || []). push ({});

bluebird bio (NASDAQ: BLUE) last released its quarterly earnings data on Monday, February 22nd. The biotech company reported earnings per share of $ 3.01 for the quarter, with analysts’ consensus estimate of $ 2.96 missing by $ 0.05. bluebird bio had a negative return on equity of 45.78% and a negative net margin of 256.84%. The company had revenue of $ 10.71 million for the quarter, compared to analyst estimates of $ 15.01 million. For the same period last year, the company had earnings per share of $ 4.04. The company’s quarterly revenue increased 7.1% year over year. Analysts assume that Bluebird Bio will show an EPS of -10.02 for the current financial year.

In other Bluebird bio news, CFO William D. Baird III sold 1,216 shares in the company on Friday, February 12. The stock sold at an average price of $ 45.52 for a total value of $ 55,352.32. Upon completion of the transaction, the CFO now holds 21,581 shares in the company valued at approximately $ 982,367.12. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In addition, Chief Financial Officer William D. Baird III sold 949 shares in the company on Wednesday, January 6. The shares were sold at an average price of $ 45.05 for a total value of $ 42,752.45. Upon completion of the transaction, the CFO now directly holds 23,194 shares in the company valued at approximately $ 1,044,889.70. The disclosure for this sale can be found here. In the past ninety days, insiders have sold 3,791 shares in the company, valued at $ 150,861. Insiders own 3.60% of the company’s stock.

Hedge funds recently added or reduced their stake in the company. Whittier Trust Co. increased its stake in Bluebird Bio by 100.0% in the fourth quarter. Whittier Trust Co. now owns 720 shares in the biotechnology company, valued at $ 32,000, after purchasing an additional 360 shares during the period. Perigon Wealth Management LLC bought a new stake in Bluebird Bio worth around $ 40,000 in the fourth quarter. Sugarloaf Wealth Management LLC acquired a new stake in Bluebird Bio worth approximately $ 43,000 in the fourth quarter. AdvisorNet Financial Inc increased its position in Bluebird Bio by 38.0% in the fourth quarter. AdvisorNet Financial Inc now owns 1,104 shares in the biotech company, valued at $ 48,000, after purchasing an additional 304 shares in the last quarter. Finally, Fieldpoint Private Securities LLC bought a new position in Bluebird Bio for $ 50,000 in the fourth quarter. Institutional investors own 94.29% of the company’s shares.

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for serious genetic diseases and cancer. Gene therapy programs include LentiGlobin for the treatment of Ã-thalassemia and sickle cell disease; and Lenti-D for the treatment of cerebral adrenoleucodystrophy.

This instant message alert was generated through narrative science technology and financial data from MarketBeat to give readers the fastest, most accurate coverage. This story has been reviewed by the editorial staff of MarketBeat prior to publication. Please send questions or comments about this story to [email protected]

So far it has been an uneven economic recovery. One area that is undoubtedly booming is the real estate market. The interesting thing, however, is that it took more than low mortgage rates to convince home buyers to take the plunge.

What it took was a pandemic. Do you think I’m kidding? Take a look at the Housing Market Index (HMI). In September, the HMI announced a preliminary rating of 83. This is an all-time high. And this is the fifth month in a row that the HMI has gone up.

Put simply, Americans have a renewed interest in spreading. For some urban dwellers, this means a flight to a place of their own. Some who own homes in more populated areas are looking for more open spaces.

Regardless of the outcome of the presidential election, the Federal Reserve has indicated that there is no rush to raise interest rates. This means that regardless of which party occupies the White House, mortgage rates should stay cheap.

There are many opportunities for investors to benefit from this real estate boom. Homebuilder stocks are a natural choice. But other companies will also benefit from the rise in home ownership.

To help you take advantage of this cutting edge sector, we have put together this special presentation.

Fill out the form below to receive the latest headlines and analyst recommendations for your stocks with our free daily email newsletter:

Sign up to MarketBeat All Access to access the full Get Research Tools from MarketBeat:

View the latest news, buy / sell ratings, SEC filings, and insider deals for your stocks. Compare your portfolio performance against leading indices and get personalized stock ideas based on your portfolio.

Get stock ideas daily with the best Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. See what stocks are up to date on social media with MarketBeat’s Trending Stock Report.

Identify stocks that match your criteria using seven unique stock screeners. See what’s happening in the market with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access subscribers can access Stock Screener, the Idea Engine, data export tools, research reports, and other premium tools.

Looking for new stock ideas? Would you like to see which stocks are moving? View our full range of financial calendars and market data tables for free.

Receive free world class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat enables individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, company buybacks, dividends, earnings, business reports, financial data, insider trading, IPOs, SEC filings, or stock splits, MarketBeat has the objective information you need to analyze stocks. Learn more.

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St # 105, Sioux Falls, SD 57103 | [Email protected] | (844) 978-6257
MarketBeat does not provide financial advice or make recommendations or offers to buy stocks or sell any securities. Learn more.
Our statement on accessibility
Don’t sell my information

© 2021 The market data provided will be delayed by at least 10 minutes and hosted by Barchart Solutions. The information is provided « as is » and is provided for informational purposes only, not for commercial or advisory purposes, and is delayed. Please refer to the disclaimer for all delays and terms of use for exchanges. Basic company data from Zacks Investment Research. As a bonus for subscribing to our e-mail newsletters, you will also receive a free subscription to the Liberty Through Wealth e-newsletter. You can unsubscribe at any time.

Enter your email address below to receive a quick daily summary of upgrades, downgrades, and new coverage from Analysts with MarketBeat.com’s FREE daily email newsletter.

Ref: https://www.marketbeat.com

Donnez votre avis et abonnez-vous pour plus d’infos

[gs-fb-comments]

Vidéo du jour: